Bone Marrow Transplantation in Treating Patients With Hematologic Cancer
Completed · Phase 4
Conditions studied: Anemia, Graft Versus Host Disease, Leukemia, Lymphoma, Multiple Myeloma and Plasma Cell Neoplasm, Myelodysplastic Syndromes
In brief
RATIONALE: Bone marrow that has been treated to remove certain white blood cells may be able to replace immune cells that were destroyed by chemotherapy or radiation therapy, and may reduce the chance of developing graft-versus-host disease following bone marrow transplantation. PURPOSE: Phase IV trial to study the incidence of graft-versus-host disease in patients who have hematologic cancer and who are undergoing bone marrow transplantation from a donor.
Key facts
- Study ID
- NCT00003398
- Run by
- University of Maryland, Baltimore
- People needed
- 45
- Starts
- 1998-09-01
- Expected to finish
- 2000-05-01
- Last updated by the study team
- 2019-10-17
Who can join
Age: any, up to 50. Sex: any. Healthy volunteers: not accepted.
Where it is running
- Marlene & Stewart Greenebaum Cancer Center, University of Maryland — Baltimore, Maryland, United States
Full record on ClinicalTrials.gov
Trial information comes from ClinicalTrials.gov and is refreshed daily. TrialsForMe does not provide medical care and does not run the studies it lists.